The lawsuit, filed in 2013, claimed Teva persuaded physicians to write prescriptions for the drugs Copaxone, a multiple sclerosis treatment, and Azilect, a Parkinson’s drug, by paying them as speakers or consultants. Many of the speaker programs were allegedly sham events.
The lawsuit claimed Teva’s actions violated the False Claims Act and the Anti-Kickback Statute, which prohibit drugmakers from compensating physicians in any way to persuade them to prescribe their drugs.
A spokesperson for Teva told the Philadelphia Business Journal the drugmaker had no comment on the settlement.
Read the full article here.
More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs
